Hosted on MSN1mon
H.C. Wainwright maintains $45 target on Cartesian stockOn Tuesday, H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a significant upside from the current trading price of $19.42.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback